The FDA on January 27, 2023, granted accelerated approval to JAYPIRCA® for Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. JAYPIRCA® is a product of Eli Lilly and Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
